文献速递瓣膜病与结构性心脏病心律失常血脂与心血管预防

依度沙班与双联抗血小板治疗对TAVR术后瓣叶血栓及脑血栓栓塞的影响:ADAPT-TAVR随机临床试验

Edoxaban Versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism After TAVR: The ADAPT-TAVR Randomized Clinical Trial.
PubMed 文献 · Circulation · 2022-04-04

ADAPT-TAVR多中心开放标签随机试验纳入229例成功TAVR且无抗凝指征患者,比较依度沙班与双联抗血小板治疗。6个月时瓣叶血栓发生率依度沙班组9.8%对双抗组18.4%(P=0.076),差异未达统计学显著;新发脑病灶及神经/神经认知功能变化两组无差异,出血事件亦无差异。研究把握度不足,结果属假说生成性质。

要点

  • TAVR术后无抗凝指征者,依度沙班较双抗未显著降低6个月瓣叶血栓发生率。
  • 两组新发脑病灶数量、体积及神经/神经认知功能恶化比例均无差异。
  • 依度沙班与双抗的出血事件发生率无差异,研究把握度不足需进一步验证。

核心结论

  • 在成功TAVR且无长期抗凝指征的患者中,依度沙班组瓣叶血栓发生率数值上低于双联抗血小板组但未达统计学显著。
  • 依度沙班与双抗对新发脑血栓栓塞及神经或神经认知功能的影响无差异。
  • 研究把握度不足,结果应视为假说生成,需进一步研究验证。

研究设计与样本

  • 多中心、开放标签随机试验,比较依度沙班与双联抗血小板治疗(阿司匹林加氯吡格雷)。
  • 纳入成功行经导管主动脉瓣置换术且无抗凝指征的患者,最终意向性治疗人群共229例。
  • 主要终点为6个月时四维计算机断层扫描诊断的瓣叶血栓发生率。

主要发现

  • 瓣叶血栓发生率依度沙班组9.8%对双抗组18.4%,绝对差异-8.5%(95%CI -17.8%至0.8%),P=0.076。
  • 脑磁共振新发脑病灶患者比例依度沙班25.0%对双抗20.2%,差异4.8%(95%CI -6.4%至16.0%),两组中位新病灶总数和体积无差异。
  • 神经和神经认知功能恶化患者比例两组无差异,任何出血或大出血事件发生率两组无差异。
  • 瓣叶血栓的存在或范围与新发脑病灶及神经或神经认知功能变化无显著关联。

关键数值与推荐

  • 主要终点瓣叶血栓:依度沙班9.8% vs 双抗18.4%,绝对差异-8.5%(95%CI -17.8%至0.8%),P=0.076。
  • 新发脑病灶患者比例:依度沙班25.0% vs 双抗20.2%,差异4.8%(95%CI -6.4%至16.0%)。

临床怎么用

  • 对于TAVR术后无长期抗凝指征的患者,依度沙班未显著优于双联抗血小板治疗,不支持常规使用依度沙班预防瓣叶血栓。
  • 瓣叶血栓与新发脑病灶及神经功能变化无显著关联,提示亚临床瓣叶血栓的临床意义需进一步明确。

局限性

  • 研究把握度不足,主要终点差异未达统计学显著,结果属假说生成性质。
  • 开放标签设计可能引入偏倚。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is unknown whether the direct oral anticoagulant edoxaban can reduce leaflet thrombosis and the accompanying cerebral thromboembolic risk after transcatheter aortic valve replacement. In addition, the causal relationship of subclinical leaflet thrombosis with cerebral thromboembolism and neurological or neurocognitive dysfunction remains unclear. METHODS: We conducted a multicenter, open-label randomized trial comparing edoxaban with dual antiplatelet therapy (aspirin plus clopidogrel) in patients who had undergone successful transcatheter aortic valve replacement and did not have an indication for anticoagulation. The primary end point was an incidence of leaflet thrombosis on 4-dimensional computed tomography at 6 months. Key secondary end points were the number and volume of new cerebral lesions on brain magnetic resonance imaging and the serial changes of neurological and neurocognitive function between 6 months and immediately after transcatheter aortic valve replacement. RESULTS: A total of 229 patients were included in the final intention-to-treat population. There was a trend toward a lower incidence of leaflet thrombosis in the edoxaban group compared with the dual antiplatelet therapy group (9.8% versus 18.4%; absolute difference, -8.5% [95% CI, -17.8% to 0.8%]; P=0.076). The percentage of patients with new cerebral lesions on brain magnetic resonance imaging (edoxaban versus dual antiplatelet therapy, 25.0% versus 20.2%; difference, 4.8%; 95% CI, -6.4% to 16.0%) and median total new lesion number and volume were not different between the 2 groups. In addition, the percentages of patients with worsening of neurological and neurocognitive function were not different between the groups. The incidence of any or major bleeding events was not different between the 2 groups. We found no significant association between the presence or extent of leaflet thrombosis with new cerebral lesions and a change of neurological or neurocognitive function. CONCLUSIONS: In patients without an indication for long-term anticoagulation after successful transcatheter aortic valve replacement, the incidence of leaflet thrombosis was numerically lower with edoxaban than with dual antiplatelet therapy, but this was not statistically significant. The effects on new cerebral thromboembolism and neurological or neurocognitive function were also not different between the 2 groups. Because the study was underpowered, the results should be considered hypothesis generating, highlighting the need for further research. REGISTRATION: URL: https://www. CLINICALTRIALS: gov. Unique identifier: NCT03284827.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Park DW, Ahn JM, Kang DY, et al. Edoxaban Versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism After TAVR: The ADAPT-TAVR Randomized Clinical Trial. Circulation. 2022. PMID: 35373583. doi:10.1161/CIRCULATIONAHA.122.059512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。